Table 1.
Patient characteristics
| Characteristics | n (%) |
|---|---|
| Age at initial treatment, years; median (range) | 59 (45–66) |
| Gender | |
| Female | 1 (4) |
| Male | 22 (96) |
| Disease stage at diagnosis | |
| I | 0 (0) |
| II | 2 (9) |
| III | 4 (17) |
| IV | 16 (70) |
| Unknown | 1 (4) |
| Extranodal disease at diagnosis | |
| No | 7 (30) |
| Yes | 16 (70) |
| Time from auto-HCT to initial maintenance treatment (months); median (range) | 3.5 (2.3–5.8) |
| MIPI at diagnosis | |
| Low | 10 |
| Intermediate | 12 |
| High | 0 |
| Unknown | 1 |
| Conditioning regimens for prior auto-HCT | |
| BEAM | 18 (78) |
| CBV | 5 (22) |
| Induction regimens | |
| R-bendamustine | 3 |
| R-HCVAD/MTX/ARA-C | 8 |
| NORDIC | 4 |
| RCHOP | 3 |
| VR-CAP | 2 |
| Ibrutinib | 1 |
| Relapsed | |
| RCHOP followed by R-HCVAD/MTX/ARA-C | 1 |
| RCHOP followed by R-bendamustine | 1 |
Abbreviations: BEAM carmustine, cytarabine, etoposide, and melphalan; CBV cyclophosphamide, carmustine, and etoposide; R, rituximab; MTX methotrexate; Ara-C cytarabine; NORDIC maximum-strength rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone alternating with rituximab, high-dose cytarabine; R-HCVAD rituximab, cyclophosphamide, vincristine, doxorubicin, dexamethasone; RCHOP rituximab, cyclophosphamide, doxorubicin vincristine, and prednisone; VR-CAP bortezomib, rituximab, cyclophosphamide, doxorubicin, prednisone